NuVasive Upgraded to “Buy” at Goldman Sachs (NUVA)
NuVasive (NASDAQ:NUVA) was upgraded by Goldman Sachs from a “neutral” rating to a “buy” rating in a research note issued on Wednesday, TheFlyOnTheWall.com reports.
In other NuVasive news, COO Keith Valentine sold 5,000 shares of the company’s stock in a transaction dated Friday, June 20th. The stock was sold at an average price of $35.00, for a total value of $175,000.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.
Several other analysts have also recently commented on the stock. Analysts at Needham & Company LLC downgraded shares of NuVasive from a “buy” rating to a “hold” rating in a research note on Wednesday, May 21st. They now have a $40.00 price target on the stock. Separately, analysts at Canaccord Genuity cut their price target on shares of NuVasive from $51.00 to $48.00 in a research note on Wednesday, April 30th. They now have a “buy” rating on the stock. Finally, analysts at Summer Street upgraded shares of NuVasive from a “neutral” rating to a “buy” rating in a research note on Wednesday, April 30th. They now have a $42.00 price target on the stock. Six investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $39.26.
Shares of NuVasive (NASDAQ:NUVA) traded down 0.13% during mid-day trading on Wednesday, hitting $34.82. The stock had a trading volume of 256,196 shares. NuVasive has a 1-year low of $22.44 and a 1-year high of $39.89. The stock’s 50-day moving average is $33.78 and its 200-day moving average is $35.0. The company’s market cap is $1.623 billion.
NuVasive (NASDAQ:NUVA) last posted its quarterly earnings results on Tuesday, April 29th. The company reported $0.29 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.23 by $0.06. The company had revenue of $177.50 million for the quarter, compared to the consensus estimate of $171.30 million. During the same quarter last year, the company posted $0.26 earnings per share. NuVasive’s revenue was up 11.3% compared to the same quarter last year. Analysts expect that NuVasive will post $1.09 EPS for the current fiscal year.
NuVasive, Inc is a medical device company, that focuses on developing minimally disruptive surgical products and procedures for the spine.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.